JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

82.77 0.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

81.36

Max

83.29

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-254M

-103M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+15.35% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.5B

13B

Ankstesnė atidarymo kaina

82.25

Ankstesnė uždarymo kaina

82.77

Naujienos nuotaikos

By Acuity

80%

20%

328 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-02 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2026-02-02 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2026-02-02 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026-02-02 23:38; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2026-02-02 23:28; UTC

Rinkos pokalbiai

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2026-02-02 23:23; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2026-02-02 22:57; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 22:22; UTC

Įsigijimai, susijungimai, perėmimai

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2026-02-02 22:08; UTC

Rinkos pokalbiai

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2026-02-02 21:51; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-02 21:49; UTC

Uždarbis

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2026-02-02 21:39; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:36; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2026-02-02 21:34; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:28; UTC

Įsigijimai, susijungimai, perėmimai

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2026-02-02 21:23; UTC

Uždarbis

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2026-02-02 21:19; UTC

Uždarbis

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2026-02-02 21:17; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2026-02-02 21:17; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:10; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:08; UTC

Uždarbis

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2026-02-02 21:07; UTC

Uždarbis

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Net $608.7M >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Rev $1.41B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Adj EPS 25c >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q EPS 24c >PLTR

2026-02-02 20:40; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

15.35% į viršų

12 mėnesių prognozė

Vidutinis 95.36 USD  15.35%

Aukščiausias 110 USD

Žemiausias 77 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

12

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

328 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat